AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
BeiGene Ltd (NASDAQ:BGNE)
180.82 USD
-3.890 2.106%Sponsored Reports
Loading...
| Previous Close (in USD) | 184.71 |
|---|---|
| Change | -3.890 2.106% |
| 52 W H/L (in USD) | 229.566/126.968 |
| EBITDA (in USD) | -1009.803M |
| PE Ratio | -- |
| Volume | 188731 |
| Diluted Eps TTM | -7.54 |
| Total Assets (in USD) | 5805.275M |
|---|---|
| Total Liabilities (in USD) | 2233.744M |
| Revenue TTM (in USD) | 2762.63M |
| Cash (in USD) | 3183.273M |
| Market Cap (in USD) | 17,319.475 M |
| Revenue Per Share TTM | 26.458 |
| Gross Profit TTM (in USD) | -511.062M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
BeiGene Ltd
BeiGene Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.
Employees: 10000
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. John V. Oyler | Co-Founder, Exec. Chairman & CEO | 1968 |
| 2. | Dr. Xiaobin Wu Ph.D. | Pres, COO & GM of China | 1962 |
| 3. | Dr. Xiaodong Wang Ph.D. | Co-Founder, Chairman of Scientific Advisory Board & Non-Exec. Director | 1963 |
| 4. | Ms. Julia Wang | CFO & Principal Accounting Officer | 1971 |
| 5. | Mr. Wang Lai | Global Head of R&D | 1977 |
| 6. | Mr. Daniel Maller | VP of Fin. & Accounting | NA |
| 7. | Ms. Mi Zhou | Sr. Director of Investor Relations | NA |
| 8. | Mr. Kevin C. Mannix | Sr. VP of Investor Relations. | NA |
| 9. | Ms. Diana Lee Francis | VP and Global Head of Quality & Regulatory Compliance | NA |
| 10. | Mr. Chan Lee | Gen. Counsel | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.930 2.657% | 74.15 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.352 0.482% | 72.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+4.320 0.973% | 443.83 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+12.300 2.546% | 485.54 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -1961.037M | -1438.588M | -1618.194M | -943.586M | -689.829M |
| Minority Interest | 0M | 0M | -3.617M | 16.15M | 14.445M |
| Net Income | -2003.815M | -1413.354M | -1600.523M | -950.578M | -673.769M |
| Selling General Administrative | 1277.852M | 990.123M | 600.176M | 388.249M | 195.385M |
| Gross Profit | -511.062M | -447.862M | -1056.66M | -570.316M | -509.49M |
| Reconciled Depreciation | 66.278M | 0.75M | 31.789M | 18.617M | 10.388M |
| Ebit | -1789.665M | -1438.735M | -1657.682M | -959.891M | -689.565M |
| Ebitda | -1788.914M | -1437.985M | -1656.836M | -958.565M | -679.177M |
| Depreciation And Amortization | 0.751M | 0.75M | 0.846M | 1.326M | 10.388M |
| Operating Income | -1789.665M | -1438.735M | -1657.682M | -959.891M | -705.769M |
| Other Operating Expenses | 3205.586M | 2615.018M | 1966.556M | 1388.103M | 903.989M |
| Interest Expense | 52.48M | -15.757M | 43.105M | 9.131M | 13.947M |
| Tax Provision | 42.778M | -25.234M | -17.671M | 6.992M | -15.796M |
| Interest Income | - | - | 1.998M | - | - |
| Net Interest Income | 52.48M | -15.757M | 1.998M | 9.131M | 13.947M |
| Income Tax Expense | 42.778M | -25.234M | -17.671M | 6.992M | -15.796M |
| Total Revenue | 1415.921M | 1176.283M | 308.874M | 428.212M | 198.22M |
| Total Operating Expenses | 1278.603M | 990.873M | 601.022M | 389.575M | 196.279M |
| Cost Of Revenue | 1926.983M | 1624.145M | 1365.534M | 998.528M | 707.71M |
| Total Other Income Expense Net | -171.372M | 0.147M | 39.488M | 16.305M | 15.94M |
| Net Income From Continuing Ops | -2003.815M | -1413.354M | -1600.523M | -950.578M | -674.033M |
| Net Income Applicable To Common Shares | -2003.815M | -1413.354M | -1596.906M | -948.628M | -673.769M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 5805.275M | 6379.29M | 8645.949M | 5600.757M | 1612.289M |
| Intangible Assets | 108.855M | 94.568M | 103.348M | 53.731M | 52.811M |
| Other Current Assets | 205.533M | 190.933M | 246.23M | 132.994M | 85.83M |
| Total Liab | 2233.744M | 1995.935M | 2402.962M | 1731.514M | 633.934M |
| Total Stockholder Equity | 3537.327M | 4383.355M | 6242.987M | 3869.243M | 978.355M |
| Other Current Liab | 784.386M | 114.342M | 479.962M | 127.808M | 152.742M |
| Common Stock | 0.135M | 0.135M | 0.133M | 0.118M | 0.079M |
| Capital Stock | 0.135M | 0.135M | 0.133M | 0.118M | 0.079M |
| Retained Earnings | -7962.05M | -7080.342M | -4966.103M | -3552.749M | -1955.843M |
| Good Will | - | 0.109M | 0.109M | 0.109M | 0.109M |
| Other Assets | 0M | 819.888M | 8645.949M | 186.8M | 108.716M |
| Cash | 3183.273M | 3869.564M | 4375.678M | 1381.95M | 618.011M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 1810.113M | 1018.02M | 1599.555M | 1075.199M | 286.044M |
| Current Deferred Revenue | 0.3M | 255.887M | 407.703M | 366.524M | - |
| Net Debt | -2253.088M | -2978.437M | -3681.034M | -819.986M | -340.669M |
| Short Term Debt | 710.316M | 353.01M | 449.49M | 348.91M | 10.814M |
| Short Long Term Debt | 688.366M | 328.969M | 427.565M | 335.015M | - |
| Short Long Term Debt Total | 930.185M | 891.127M | 694.644M | 561.964M | 277.342M |
| Other Stockholder Equity | 11598.688M | 11540.979M | 11191.007M | 7414.932M | 2942.12M |
| Property Plant Equipment | - | 955.906M | 587.605M | 357.686M | 324.922M |
| Total Current Assets | 4203.414M | 4713.456M | 7613.88M | 4960.69M | 1172.696M |
| Long Term Investments | 89.644M | 91.779M | 100.792M | 49.344M | - |
| Short Term Investments | 2.6M | 665.251M | 2241.962M | 3268.725M | 364.728M |
| Net Receivables | 395.886M | 173.168M | 500.175M | 79.673M | 72.81M |
| Long Term Debt | 197.618M | 209.148M | 202.113M | 183.637M | 240.695M |
| Inventory | 416.122M | 282.346M | 242.626M | 89.293M | 28.553M |
| Accounts Payable | 315.111M | 294.781M | 262.4M | 231.957M | 122.488M |
| Accumulated Other Comprehensive Income | -99.446M | -77.417M | 17.95M | 6.942M | -8.001M |
| Non Currrent Assets Other | -18.71M | -186.456M | 30.652M | 24.623M | 2.476M |
| Non Current Assets Total | 1601.861M | 845.946M | 1032.069M | 640.067M | 439.593M |
| Capital Lease Obligations | 44.201M | 58.558M | 64.966M | 43.312M | 36.647M |
| Long Term Debt Total | - | - | 202.113M | 183.637M | 240.695M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 1077.123M | 955.51M | -2939.333M | 712.775M | -458.479M |
| Total Cashflows From Investing Activities | 1077.123M | 640.659M | -3168.366M | 554.163M | -637.613M |
| Total Cash From Financing Activities | -18.971M | 3636.911M | 5202.826M | 85.68M | 1690.537M |
| Net Income | -2003.815M | -1413.354M | -1600.523M | -950.578M | -674.033M |
| Change In Cash | -507.85M | 2992.882M | 769.23M | -119.938M | 501.111M |
| Begin Period Cash Flow | 4382.887M | 1390.005M | 620.775M | 740.713M | 239.602M |
| End Period Cash Flow | 3875.037M | 4382.887M | 1390.005M | 620.775M | 740.713M |
| Total Cash From Operating Activities | -1496.619M | -1298.723M | -1283.461M | -750.269M | -547.717M |
| Depreciation | 66.278M | 46.457M | 31.789M | 18.617M | 10.388M |
| Other Cashflows From Investing Activities | - | -51.909M | -111.525M | -69M | -108.851M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -56.689M | -153.333M | -58.906M | -12.311M | -5.312M |
| Sale Purchase Of Stock | - | 3535.378M | 4325.118M | 51.004M | 29.248M |
| Other Cashflows From Financing Activities | 398.11M | 516.049M | 1115.117M | 118.493M | 65.904M |
| Capital Expenditures | 469.099M | 314.851M | 229.033M | 158.612M | 140.836M |
| Change In Working Capital | 132.391M | -118.345M | 150.584M | -10.833M | -17.214M |
| Other Non Cash Items | 3.306M | -13.108M | -20.985M | 67.603M | 67.964M |
| Free Cash Flow | -1965.718M | -1613.574M | -1512.494M | -908.881M | -688.553M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | American Funds Growth Fund of Amer A | 1 year ago | 304995 |
| 2. | American Funds New Perspective A | 1 year ago | 2806560 |
| 3. | Capital Group New Perspective Comp | 1 year ago | 2806560 |
| 4. | Vanguard PRIMECAP Inv | 1 year ago | 2280190 |
| 5. | AF High Growth (AFRIS) | 1 year ago | 1808004 |
| 6. | American Funds New World A | 1 year ago | 1155057 |
| 7. | American Funds Europacific Growth A | 1 year ago | 1053592 |
| 8. | Capital Group EuroPacific Growth Comp | 1 year ago | 1053592 |
| 9. | Vanguard Capital Opportunity Inv | 1 year ago | 1030021 |
| 10. | Global Balanced (AFRIS) | 1 year ago | 829416 |
| 11. | PRIMECAP Odyssey Aggressive Growth | 1 year ago | 709157 |
| 12. | PRIMECAP Odyssey Growth | 1 year ago | 681427 |
| 13. | Fidelity Growth Compy Commingled Pl O | 1 year ago | 646372 |
| 14. | T. Rowe Price Health Sciences | 1 year ago | 636212 |
| 15. | iShares Biotechnology ETF | 1 year ago | 596432 |
| 16. | T. Rowe Price International Growth Eq | 1 year ago | 497712 |
| 17. | T. Rowe Price International Stock | 1 year ago | 497712 |
| 18. | Fidelity Growth Company Fund | 1 year ago | 474900 |
| 19. | T. Rowe Price International Gr Eq Tr-D | 1 year ago | 417480 |
| 20. | Baillie Gifford WW L/T Glb Gr B USD Acc | 1 year ago | 332280 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Baker Bros Advisors LP | 1 year ago | 10568897 |
| 2. | Capital Research & Mgmt Co - Division 3 | 1 year ago | 7064428 |
| 3. | Hillhouse Capital Advisors, Ltd. | 1 year ago | 5176906 |
| 4. | PRIMECAP Management Company | 1 year ago | 5001839 |
| 5. | Baillie Gifford & Co Limited. | 1 year ago | 3728730 |
| 6. | Temasek Holdings Ltd. | 1 year ago | 3014171 |
| 7. | T. Rowe Price Associates, Inc. | 1 year ago | 2026094 |
| 8. | FMR Inc | 1 year ago | 1721303 |
| 9. | Capital International Inc /ca/ | 1 year ago | 858364 |
| 10. | BlackRock Inc | 1 year ago | 854876 |
| 11. | Boxer Capital LLC | 1 year ago | 500000 |
| 12. | Amvescap Plc. | 1 year ago | 475885 |
| 13. | Goldman Sachs Group Inc | 1 year ago | 428678 |
| 14. | Artal Group S A | 1 year ago | 404480 |
| 15. | PUBLIC INVESTMENT FUND | 1 year ago | 354385 |
| 16. | Vestal Point Capital LP | 1 year ago | 325000 |
| 17. | First Trust Advisors L.P. | 1 year ago | 219741 |
| 18. | Capital International Sarl | 1 year ago | 191942 |
| 19. | Bank of America Corp | 1 year ago | 176392 |
| 20. | M&G INVESTMENT MANAGEMENT LTD | 1 year ago | 173266 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...